Medtronic, a global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions, completed the acquisition of Affera, a medical technology company dedicated to delivering unrivaled innovative solutions to address the rapidly growing demands for cardiac arrhythmia treatment. Financial terms were not disclosed. "This acquisition marks an important growth milestone for our cardiac ablation portfolio. We're incredibly proud to have led the industry with the introduction of the proven safe and effective cryoablation technology; and now these new additions to our portfolio help support a leap forward in our commitment to build a comprehensive portfolio and help physicians achieve the best outcomes for patients," Rebecca Seidel, Medtronic President.